Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

Adjuvant immunotherapies targeting CTLA4 or PD-1 recently demonstrated efficacy in the treatment of earlier stages of human cancer. We previously demonstrated using mouse spontaneous metastasis models that neoadjuvant immunotherapy and surgery was superior, compared to surgery and adjuvant immunothe...

Full description

Bibliographic Details
Main Authors: Jing Liu, Jake S. O’Donnell, Juming Yan, Jason Madore, Stacey Allen, Mark J. Smyth, Michele W. L. Teng
Format: Article
Language:English
Published: Taylor & Francis Group 2019-05-01
Series:OncoImmunology
Subjects:
neoadjuvant immunotherapy
surgery
scheduling
metastases
iraes
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1581530

Internet

http://dx.doi.org/10.1080/2162402X.2019.1581530

Similar Items